{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T03:27:07Z","timestamp":1768274827758,"version":"3.49.0"},"reference-count":28,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[1995,7,1]],"date-time":"1995-07-01T00:00:00Z","timestamp":804556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Substance Abuse"],"published-print":{"date-parts":[[2007,7]]},"abstract":"<jats:p> Women are under-represented in opioid dependency treatment, yet national statistics indicate that, as the non-medical use of prescription pain relievers rises, more women will require this treatment. Important considerations for the treatment of opioid-dependency in women include high rates of psychiatric illness, concerns regarding substance abuse and treatment in pregnancy, high rates of history of trauma, relationship dynamics that put women at risk for sexually transmitted diseases, and social factors such as lower economic status and responsibilities as care givers. Traditional approaches to opioid-dependency treatment, such as methadone maintenance programs (MMPs), have not consistently addressed these needs and do not provide flexible care and anonymity. Recent data suggest that, in comparison to MMPs, a greater percentage of women are entering office-based treatment. Yet it is unclear whether physicians\u2019 offices will be equipped to adequately handle women's treatment needs. Nonetheless office-based treatment may provide a solution for women concerned about anonymity, stigma, and the requirement of daily visits to a MMP. <\/jats:p>","DOI":"10.1300\/j465v28n02_02","type":"journal-article","created":{"date-parts":[[2007,8,21]],"date-time":"2007-08-21T12:30:48Z","timestamp":1187699448000},"page":"3-8","source":"Crossref","is-referenced-by-count":13,"title":["Women and Opioid Dependence Treatment"],"prefix":"10.1177","volume":"28","author":[{"given":"Emlyn S.","family":"Jones","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Fiellin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[1995,7,1]]},"reference":[{"key":"bibr1-J465v28n02_02","volume-title":"Women in substance abuse treatment: Results from the Alcohol and Drug Services Study (ADSS)","author":"Brady T M","year":"2005"},{"key":"bibr2-J465v28n02_02","unstructured":"Substance Abuse and Mental Health Services Administration. 2003. Results from the 2002 National Survey on Drug Use and Health: National Findings Rockville, MD (Office of Applied Studies, NHSDA Series H-22, DHHS Publication No. SMA 03\u20133836)"},{"key":"bibr3-J465v28n02_02","unstructured":"Office of Applied Statistics, Substance Abuse and Mental Health Services Administration. Nonmedical Users of Pain Relievers: Characteristics of Recent Initiates Accessed on Oct. 4 2006 at http:\/\/www.oas.samhsa.gov\/2k6\/pain\/pain.pdfThe NSDUH Report. 2006 (22)"},{"key":"bibr4-J465v28n02_02","unstructured":"Office of National Drug Control Policy. Drug Facts: women and drugs Accessed on Oct. 4 2006 at http:\/\/www.whitehousedrugpolicy.gov\/drugfact\/women\/index.html"},{"key":"bibr5-J465v28n02_02","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2006.05.012"},{"key":"bibr6-J465v28n02_02","doi-asserted-by":"publisher","DOI":"10.1016\/S0740-5472(99)00091-4"},{"key":"bibr7-J465v28n02_02","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2006.01321.x"},{"key":"bibr8-J465v28n02_02","doi-asserted-by":"publisher","DOI":"10.3109\/00952999709016897"},{"key":"bibr9-J465v28n02_02","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2002.10399975"},{"key":"bibr10-J465v28n02_02","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2005.07.003"},{"key":"bibr11-J465v28n02_02","doi-asserted-by":"publisher","DOI":"10.1037\/0893-164X.18.2.180"},{"issue":"5","key":"bibr12-J465v28n02_02","first-page":"517","volume":"16","author":"Gilbert L","year":"2001","journal-title":"Violence Vict"},{"issue":"5","key":"bibr13-J465v28n02_02","first-page":"452","volume":"67","author":"Gilbert L","year":"2000","journal-title":"Mt Sinai J Med"},{"key":"bibr14-J465v28n02_02","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-005-3899-6"},{"key":"bibr15-J465v28n02_02","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4603(02)00266-6"},{"key":"bibr16-J465v28n02_02","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(02)00332-0"},{"key":"bibr17-J465v28n02_02","doi-asserted-by":"publisher","DOI":"10.1081\/ADA-120029864"},{"key":"bibr18-J465v28n02_02","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.1995.10471698"},{"key":"bibr19-J465v28n02_02","doi-asserted-by":"publisher","DOI":"10.1037\/0893-164X.15.3.177"},{"key":"bibr20-J465v28n02_02","doi-asserted-by":"publisher","DOI":"10.1081\/JA-120017653"},{"key":"bibr21-J465v28n02_02","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(01)00153-3"},{"issue":"6","key":"bibr22-J465v28n02_02","first-page":"1","volume":"15","author":"National Institutes of health","year":"1997","journal-title":"NIH Consensus Statement"},{"key":"bibr23-J465v28n02_02","doi-asserted-by":"publisher","DOI":"10.3109\/00952998709001513"},{"key":"bibr24-J465v28n02_02","doi-asserted-by":"publisher","DOI":"10.1081\/ADA-120018838"},{"key":"bibr25-J465v28n02_02","doi-asserted-by":"publisher","DOI":"10.1177\/104973239700700107"},{"key":"bibr26-J465v28n02_02","unstructured":"Substance Abuse and Mental Health Services Administration. Drug Addiction Treatment Act of 2000 (DATA 2000) Accessed on Oct. 4 2006 at http:\/\/www.buprenorphine.samhsa.gov\/data.html"},{"key":"bibr27-J465v28n02_02","unstructured":"Substance Abuse and Mental Health Services Administration. Evaluation of the buprenorphine waiver program Accessed on Oct. 4 2006 at http:\/\/www.buprenorphine.samhsa.gov\/findings.pdf"},{"key":"bibr28-J465v28n02_02","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2004.12.008"}],"container-title":["Substance Abuse"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1300\/J465v28n02_02","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1300\/J465v28n02_02","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T08:58:44Z","timestamp":1741683524000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1300\/J465v28n02_02"}},"subtitle":["Office-Based versus Opioid Treatment Program-Based Care?"],"short-title":[],"issued":{"date-parts":[[1995,7,1]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,7]]}},"alternative-id":["10.1300\/J465v28n02_02"],"URL":"https:\/\/doi.org\/10.1300\/j465v28n02_02","relation":{},"ISSN":["0889-7077","1547-0164"],"issn-type":[{"value":"0889-7077","type":"print"},{"value":"1547-0164","type":"electronic"}],"subject":[],"published":{"date-parts":[[1995,7,1]]}}}